Imotil2 mg

Imotil is an antidiarrheal agent with the following evidence-based indications:

• Acute nonspecific diarrhea (FDA-approved) - for symptomatic relief in patients 2 years of age and older.
• Chronic diarrhea associated with inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis in remission) (FDA-approved) - for use in adults under medical supervision.
• Reduction of ileostomy output (FDA-approved) - to decrease the volume of discharge from ileostomies.
• Traveler's diarrhea (guideline-supported, adjunct use) - commonly recommended as adjunct symptomatic therapy, often together with an appropriate antimicrobial when indicated, in adults without fever or bloody stools.

Imotil is not indicated for conditions where inhibition of intestinal motility should be avoided (see Contraindications).

Each dosage form of Loperamide contains Loperamide Hydrochloride as the active ingredient. It is commonly available as:

• Capsule/Tablet: 2 mg
• Oral solution/Syrup: 1 mg/5 mL

Excipients vary by manufacturer and formulation.

Imotil is a synthetic antidiarrheal agent chemically related to the opioid class but formulated to act primarily on peripheral opioid receptors in the gut wall, with minimal clinically significant central nervous system penetration at recommended doses. It is widely used for symptomatic control of acute and chronic diarrhea.

Imotil is available in Bangladesh in capsule, tablet, and oral solution forms and is marketed under various brand names.

Boxed Warning

Taking more than the recommended dose of Imotil can cause serious heart problems, including QT interval prolongation, Torsades de Pointes, other ventricular arrhythmias, cardiac arrest, and death. Cases have been reported in individuals intentionally taking higher-than-recommended doses of Imotil in attempts to self-treat opioid withdrawal symptoms or to achieve euphoria. Patients and caregivers should be counseled to take only the recommended dose.

Imotil belongs to the therapeutic class of antidiarrheal agents, specifically the peripherally-acting opioid-receptor agonist antidiarrheals.

Loperamide acts as an agonist at peripheral mu-opioid receptors located in the myenteric plexus of the intestinal wall. This action:

• Slows intestinal motility by inhibiting peristalsis, thereby increasing intestinal transit time.
• Reduces fecal volume and fluid/electrolyte loss.
• Increases tone of the anal sphincter, reducing incontinence and urgency.

Because Loperamide undergoes extensive first-pass hepatic metabolism and is a substrate of P-glycoprotein at the blood-brain barrier, it has minimal CNS opioid effects at recommended doses. However, at supratherapeutic doses, P-glycoprotein efflux can be saturated/overwhelmed, allowing CNS penetration and cardiac toxicity via hERG potassium channel blockade, which underlies the boxed warning for Loperamide. Onset of action is typically within 1 hour; the elimination half-life is approximately 9-14 hours, and it is primarily eliminated in feces with a smaller fraction excreted in urine as metabolites.

Imotil is administered orally, with or without food. Capsules/tablets should be swallowed whole with water; oral solution should be measured accurately using a calibrated measuring device. Adequate oral rehydration (fluids and electrolytes) should be maintained alongside Imotil therapy, especially in children and the elderly.

Imotil has the following clinically significant interactions:

• CYP3A4 and/or P-glycoprotein inhibitors (e.g., itraconazole, ritonavir, quinidine, gemfibrozil): Co-administration can substantially increase plasma concentrations of Imotil, increasing the risk of serious cardiac arrhythmias including QT prolongation and Torsades de Pointes; concurrent use should be avoided or approached with extreme caution and close monitoring.
• Other QT-prolonging drugs (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics): Additive risk of QT prolongation when combined with Imotil, particularly at higher doses; avoid combination where possible.
• Other CNS depressants or opioids: May increase sedation or CNS depression risk when used with Imotil, particularly at supratherapeutic doses.

Side effects of Imotil are generally uncommon at recommended doses but may include:

• Constipation, abdominal pain or cramping, nausea, vomiting, dry mouth
• Dizziness, drowsiness, fatigue, headache
• Flatulence, abdominal distension
• Skin rash and, rarely, hypersensitivity reactions including angioedema

Serious but rare adverse effects, generally associated with doses exceeding the recommended amount, include QT/QRS prolongation, Torsades de Pointes, other ventricular arrhythmias, syncope, cardiac arrest, and paralytic ileus (see Boxed Warning and Overdose Effects).

Pregnancy: Animal reproduction studies have not shown evidence of harm to the fetus at recommended human doses; however, adequate and well-controlled studies in pregnant women are lacking. Imotil should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

Lactation: Small amounts of Imotil may be excreted into human breast milk. Use during breastfeeding is generally not recommended unless a physician determines that the benefit outweighs the potential risk to the infant.

The following precautions apply to the use of Imotil:

• Do not exceed the recommended dose of Imotil under any circumstance, due to the risk of serious cardiac toxicity (see Boxed Warning).
• Discontinue Imotil and consult a physician promptly if diarrhea persists beyond 48 hours, worsens, or is accompanied by fever or blood in the stool, as this may indicate a condition where Imotil should not be used.
• Use with caution in patients with hepatic impairment, as reduced hepatic metabolism may increase systemic exposure and risk of CNS/cardiac toxicity.
• Discontinue promptly if abdominal distension, constipation, or ileus develops.
• Avoid co-administration with drugs that inhibit CYP3A4/P-glycoprotein or prolong the QT interval (see Interactions).
• Not intended for chronic use except under physician supervision for approved indications such as IBD-associated chronic diarrhea.
• Keep out of reach of children, as accidental ingestion or intentional misuse can cause serious or fatal cardiac events.

Overdose of Imotil can cause serious or life-threatening cardiac toxicity, including QT/QRS interval prolongation, Torsades de Pointes, other ventricular arrhythmias, syncope, and cardiac arrest, as well as CNS depression (drowsiness, stupor, miosis, respiratory depression) and paralytic ileus, particularly with doses well above the recommended maximum.

If overdose of Imotil is suspected, seek immediate emergency medical attention or contact a poison control center right away. Do not attempt home treatment. Prolonged cardiac monitoring (at least 24 hours) is generally required in a hospital setting because of delayed gastrointestinal absorption; management is supportive and directed by medical professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric: Imotil is contraindicated in children under 2 years of age due to risk of serious, potentially fatal, adverse effects including respiratory depression and cardiac toxicity. Use in children 2 years and older should follow weight/age-based dosing under medical guidance (see Pediatric Uses).

Elderly: No specific dose adjustment is generally required, but elderly patients should be monitored for constipation and dehydration.

Hepatic impairment: Use with caution; reduced first-pass metabolism may increase plasma concentrations of Imotil and the risk of CNS/cardiac toxicity. Monitor closely for signs of toxicity.

Renal impairment: No well-established dose adjustment is required, as renal elimination is a minor pathway; use with usual caution.

For acute diarrhea, Imotil should generally be used for no more than 48 hours; if diarrhea persists beyond this period or worsens, treatment should be stopped and a physician consulted. For chronic diarrhea associated with inflammatory bowel disease, duration of Imotil therapy is determined by the treating physician based on ongoing clinical need, using the lowest effective dose.

Loperamide is classified as an antidiarrheal agent within the peripherally-acting opioid-receptor agonist class.

Loperamide works by binding to opioid receptors on the smooth muscle of the intestinal wall, which inhibits the release of acetylcholine and prostaglandins. This reduces propulsive peristalsis, prolongs intestinal transit time, and increases the absorption of water and electrolytes from the gut lumen, thereby reducing stool frequency and volume. Loperamide also increases resting anal sphincter tone.

Category C

Imotil is contraindicated in children under 2 years of age due to the risk of serious, potentially fatal adverse effects, including respiratory depression and cardiac toxicity.

For children 2 years and older with acute diarrhea, first-day dosing of Imotil is weight/age-based and should not exceed labeled maximums:

Subsequent doses of Imotil should only be given after a loose stool, and total daily dose should not exceed the first-day amount. Safety and efficacy of Imotil for chronic diarrhea in children have not been established.